IRIS
BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.807
EU - Europa 896
AS - Asia 796
SA - Sud America 250
AF - Africa 46
OC - Oceania 1
Totale 3.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.791
HK - Hong Kong 302
SG - Singapore 285
IE - Irlanda 269
BR - Brasile 231
RU - Federazione Russa 229
SE - Svezia 161
CN - Cina 136
IT - Italia 110
GB - Regno Unito 57
CI - Costa d'Avorio 26
DE - Germania 15
AT - Austria 12
IN - India 12
FR - Francia 11
FI - Finlandia 9
TR - Turchia 9
IQ - Iraq 7
MA - Marocco 7
UA - Ucraina 7
AR - Argentina 6
AE - Emirati Arabi Uniti 5
BD - Bangladesh 5
CA - Canada 5
JP - Giappone 5
PK - Pakistan 5
MX - Messico 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
EC - Ecuador 3
NG - Nigeria 3
VE - Venezuela 3
ZA - Sudafrica 3
BE - Belgio 2
BO - Bolivia 2
CL - Cile 2
GR - Grecia 2
HN - Honduras 2
JM - Giamaica 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
NL - Olanda 2
NP - Nepal 2
PL - Polonia 2
PY - Paraguay 2
SN - Senegal 2
VN - Vietnam 2
AL - Albania 1
AU - Australia 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
ES - Italia 1
GE - Georgia 1
IR - Iran 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 3.796
Salva come PNG Salva come JPEG
Città #
Hong Kong 302
Chandler 297
Dublin 269
Ashburn 228
Boardman 157
Fairfield 123
Singapore 122
Lawrence 104
Princeton 104
San Diego 59
Washington 52
New York 51
Des Moines 49
Moscow 45
Dallas 42
Seattle 30
Abidjan 26
London 26
Turin 24
Redmond 21
Los Angeles 19
São Paulo 18
The Dalles 17
Pune 11
Guangzhou 10
Belo Horizonte 9
Cambridge 9
Vienna 9
Woodbridge 9
Ancona 8
Houston 8
Shanghai 8
Helsinki 7
Nuremberg 7
Rio de Janeiro 7
Ribeirão Preto 6
Contagem 5
Marche 5
Porto Alegre 5
San Francisco 5
Bologna 4
Boydton 4
Brasília 4
Casablanca 4
Clifton 4
Hangzhou 4
Hounslow 4
Macerata 4
Recife 4
Santa Clara 4
Southwark 4
Tashkent 4
Tokyo 4
Ankara 3
Baghdad 3
Baku 3
Brooklyn 3
Chiswick 3
Fortaleza 3
Islington 3
Kilburn 3
Munich 3
Petrolina 3
Prescot 3
Rome 3
Tianjin 3
Volta Redonda 3
Wandsworth 3
Wuhan 3
Aci Catena 2
Amman 2
Ann Arbor 2
Anápolis 2
Aparecida de Goiânia 2
Araxá 2
Beijing 2
Bishkek 2
Boston 2
Brussels 2
Bursa 2
Campo Grande 2
Campos dos Goytacazes 2
Caxias do Sul 2
Changsha 2
Chicago 2
Curitiba 2
Dakar 2
Dubai 2
Dueville 2
Erbil 2
Florianópolis 2
Franca 2
Genoa 2
Goiânia 2
Hanoi 2
Ikeja 2
Jaú 2
Jiaxing 2
Jinhua 2
Johannesburg 2
Totale 2.475
Salva come PNG Salva come JPEG
Nome #
The application of cancer stem cell model in malignant mesothelioma 76
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 71
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 66
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 65
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 61
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 61
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 58
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 52
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 52
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 52
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 51
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 50
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 49
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 49
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 48
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 48
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 48
How much of familial breast cancer risk is currently explained by the known genes? 48
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 47
Cancer and the microbiome: Potential applications as new tumor biomarker 46
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 46
Germline copy number variation in the YTHDC2 gene: Does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility? 46
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 45
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 45
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 45
Sorafenib for the treatment of breast cancer 45
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 43
New generation anaplastic lymphoma kinase inhibitors 43
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 43
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 42
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 42
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 42
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 42
Bortezomib: A new pro-apoptotic agent in cancer treatment 42
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 42
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 41
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 41
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 40
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 40
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 40
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 39
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 38
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 38
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 38
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 38
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 37
VIPoma and PPoma 37
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 37
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 36
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 36
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 36
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 36
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 35
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 35
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 35
The role of targeted therapy for gastrointestinal tumors 35
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 35
EGFR genomic alterations in cancer: prognostic and predictive values 34
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 34
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 33
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 33
A headlight on liquid biopsies: a challenging tool for breast cancer management 33
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 33
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 32
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 32
Anti-endothelin drugs in solid tumors 31
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 31
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 30
Monoclonal antibodies in gastrointestinal cancers 29
Fully human antibodies for malignant pleural mesothelioma targeting 29
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 28
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 27
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 27
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 27
Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy 27
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 26
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 26
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 25
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 25
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 25
Nintedanib in NSCLC: Evidence to date and place in therapy 25
Targeted therapies in hepatocellular carcinoma 25
Colorectal cancer 25
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 25
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 24
Dietary restriction: could it be considered as speed bump on tumor progression road? 24
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 24
MicroRNAs in colorectal cancer stem cells: New regulators of cancer stemness? 24
Sex steroids, carcinogenesis, and cancer progression 24
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 23
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 23
Multisciplinary management of patients with liver metastasis from colorectal cancer 23
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 23
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 23
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 22
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 22
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 22
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 21
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 21
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 21
Totale 3.715
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.589
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.589
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022515 0 0 0 0 0 0 0 0 237 13 153 112
2022/20231.116 106 67 91 59 78 196 2 55 343 5 81 33
2023/2024846 157 17 79 122 158 185 18 27 0 9 20 54
2024/20251.521 91 176 29 43 59 138 238 87 472 103 85 0
Totale 3.998